Gene · 3423
Papers1,392
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 1,392
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Development and validation of an ELISA-based assay for detecting anti-idursulfase beta IgE antibodies in human serum using a conjugated IgG-IgE positive control antibody. | J Immunol Methods | 2026 | 42767399 | PubTator, text mining | PubMed |
| Longitudinal Assessment of Cognitive Development in 23 Patients With Mucopolysaccharidosis (MPS) Type II: Results of up to 14 Years of Follow-Up. | J Inherit Metab Dis | 2026 | 42723346 | PubTator, text mining | PubMed |
Interim analysis of post-marketing surveillance study of intracerebroventricular idursulfase therapy for neuronopathic mucopolysaccharidosis type II: Safety and effectiveness in clinical practice in Japan. | Mol Genet Metab | 2026 | 42679455 | PubTator, text mining | PubMed |
| Quantum Statistical Behaviors of Carriers in Strong Inversion Layers Associated with Mobility and Threshold Voltage in FinFET Transistors. | Micromachines (Basel) | 2026 | 42513019 | PubTator, text mining | PubMed |
| Sustained clinical benefit of idursulfase beta in mucopolysaccharidosis II: two-year experience from a phase 3 extension study including patients switched from idursulfase. | Orphanet J Rare Dis | 2026 | 42421116 | PubTator, text mining | PubMed |
| Integrative multi-omics analysis identifies a mitochondrial dysfunction-associated diagnostic signature, molecular subtypes, and drug repurposing candidates for keloid disease. | Burns | 2026 | 42413388 | PubTator, text mining | PubMed |
| Tividenofusp Alfa: First Approval. | Mol Diagn Ther | 2026 | 42313339 | PubTator, text mining | PubMed |
| Analytical Validation of MyProstateScore 2.0-Active Surveillance: A Urinary-Based Clinical RT-PCR Prostate Cancer Assay. | Diagnostics (Basel) | 2026 | 42196852 | PubTator, text mining | PubMed |
| Merging evans syndrome with mucopolysaccharidosis type II: a case report. | Front Pediatr | 2026 | 42158367 | PubTator, text mining | PubMed |
| Harmonizing Perspectives on MPS II Care in Türkiye: A Delphi Study Towards Treatment Management Consensus. | Healthcare (Basel) | 2026 | 42121657 | PubTator, text mining | PubMed |
| Expression of sulfate pathway genes in human neurodevelopment. | J Neurogenet | 2026 | 42101182 | PubTator, text mining | PubMed |
| Label-free quantitative urinary proteomics for non-invasive biomarker discovery in endometrial cancer. | Front Med (Lausanne) | 2026 | 42040568 | PubTator, text mining | PubMed |
| A novel IDS variant associated with an isolated ocular phenotype in Hunter syndrome. | Doc Ophthalmol | 2026 | 42033570 | PubTator, text mining | PubMed |
| Evolution of trans-isoprenyl diphosphate synthases in the plant kingdom. | Plant Physiol | 2026 | 42025326 | PubTator, text mining | PubMed |
| A North Carolina newborn screening pilot for mucopolysaccharidosis II: Evaluating endogenous nonreducing end glycosaminoglycan analysis and IDS sequencing as higher-tier testing options. | Genet Med | 2026 | 42017346 | PubTator, text mining | PubMed |
| Revealing the role of a novel IDS gene mutation in mucpolysaccharidosis type II: insights from computational analysis. | Front Mol Biosci | 2026 | 42005589 | PubTator, text mining | PubMed |
| The Critical Role of Fractionated Urine Glycosaminoglycans in the Evaluation of Mucopolysaccharidosis Type II in Four Unrelated Families. | Am J Med Genet A | 2026 | 41968348 | PubTator, text mining | PubMed |
| Estimating population structure using epigenome-wide methylation data. | Brief Bioinform | 2026 | 41902502 | PubTator, text mining | PubMed |
| Subtle cellular phenotypes inform pathological and benign genetic mutants in the Iduronate-2 sulfatase gene. | Hum Mol Genet | 2026 | 41818734 | PubTator, text mining | PubMed |
| Plasma proteomic profile reveals persistent immune activation in post-acute sequelae of SARS-CoV-2 infection. | Front Immunol | 2026 | 41808838 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3423/papers